Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005609 · ClinicalTrials.gov registry record · Phase 2
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005609: Completed Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
NCT00005609 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005609, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who have Waldenstrom's macroglobulinemia.
Interventions
- BIOLOGICAL rituximab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-04 |
| Est. Completion | 2004-02 |
| Phase | Phase 2 |
What the finished NCT00005609 record still lists
NCT00005609 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which rituximab is the first listed.
NCT00005609 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005609 about?
NCT00005609 is a clinical study titled "Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia". RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who have Waldenstrom's macroglobulinemia.
What is the current status of trial NCT00005609?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-04. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00005609?
The interventions under investigation include: rituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005609?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia